CD95 is a cell surface receptor involved in apoptotic signal transmission. Deregulation of this pathway results in down regulation of apoptosis and subsequent persistence of a malignant clone. A single nucleotide polymorphism (SNP) resulting in guanine-to-adenine (G > A) transition in the CD95 promoter region (position −1377) is thought to reduce stimulatory protein 1 (SP1) transcription factor binding and decrease CD95 expression. The purpose of this study was to examine a genetic polymorphism in the core promoter of CD95 is associated with the frequency. G-1377A in the CD95 promoter region was genotyped by polymerase chain reaction and restriction endonuclease analysis and sequenced of the CD95
Introduction
The CD95 (Apo-1/Fas) receptor-ligand system is one of the key regulators of apoptosis and is particularly important for the maintenance of lymphocyte homeostasis. The CD95 receptor (also termed Apo-1 or FAS) is a type I transmembrane protein which belongs to the tumor necrosis factor receptor superfamily [1] . In the human, germline and somatic mutations of the CD95 gene are associated with a high risk of both lymphoid and solid tumors. The CD95 receptor is expressed in the majority of human cells, and signals apoptosis upon interaction with the CD95 ligand [2] . Binding to the receptor by the CD95 ligand triggers receptor trimerization and subsequent assembly of the death-inducing signaling complex [3] . This mechanism of CD95 mediated apoptosis is believed to be involved in the removal of autoreactive lymphocytes during normal development of the immune system [4] . Dysregulation of this pathway is believed to result in down regulation of apoptosis, allowing subsequent persistence of a malignant clone [5] . Germline mutations or deletions within CD95, resulting in a loss or a reduction in receptor function, have been shown to cause autoimmune lymphoproliferative syndrome as well as an overall increased risk of hematological malignancies [6] . CD95 expression levels may also be affected by mutations or polymorphisms in the promoter region of CD95, when they affect the transcription binding sites. A SNP resulting in guanine-to-adenine (G > A) transition in the CD95 promoter region occurs at position −1377, affecting a stimulatory protein 1 (SP1) transcription factor binding site [5] . An adenine residue at this position significantly reduces SP1 binding compared to guanine residue, causing a decrease in CD95 expression [5] . Many cell types express CD95 including cells of B-lineage [7] , T-lineage [8] and acute leukemias. Myeloblasts are known to express high levels of CD95, and functional deficiencies of CD95 signaling have been shown to be important in several subtypes of acute myeloid leukemia (AML), providing further evidence for CD95-mediated apoptosis in the etiology of AML [9] . CD95 expression has been associated with a better prognosis in B-cell lymphomas and with responsiveness to chemotherapy in AML, whereas most primary T-cell leukemias are constitutively resistant against CD95-induced apoptosis [10] . The purpose of the study is to investigate CD95 G-1377A SNP in patients with acute leukemia and to determine the frequency of the polymorphism between patients and healthy individuals.
Material and Methods
Study population consisted of 248 patients and control individuals aged between 1 and 15 years, who were admitted to Losante Children's and Adult Hospital.
The study group consists of 64 males and 82 females. The patient blood was collected from Losante Children Hospital, Turkey. One hundred forty-six children with leukemia were included in the study. Healthy groups were selected among healthy unrelated subjects from Turkey (n:102). An informed written consent was obtained from all the patients' parents. The study is carried out in accordance Chi-square test, independent sample t-test, or Mann-Whitney U-test, as appropriate for the type of data being analyzed, were used to assess the statistical significance of the difference between the two groups. P values less than 0.05 were considered statistically significant.
Results
Single Heterozygous patients diagnosed with 29 ALL, 4 AML, 3 biphenotypic acute leukemia and one patient diagnosed with APL. 31% of 13 patients with AML (n: 4) were found as heterozygous, while heterozygous percentage of ALL patients was 24% (n: 29). The prevalence of CD95 G-1377A polymorphisms was determined for 102 healthy individuals. Among 102 healthy individuals, CD95 G-1377A polymorphisms were found in 12 cases (11.7%) ( Table 1 and Table 2 ). There were significant differences in the genotype frequency for CD95 G-1377A polymorphism between the groups (Table 2 ).
Discussion
In the literature, numerous studies researched in different population, showed correlation on between genetic polymorphisms of CD95 in different diseases. However, there are inadequate studies in development of childhood leukemia. Functional G-1377A SNP in CD95 gene that the development of apoptosis and cancer plays an important role has been reported in many studies. This SNP was reported that the risk of developing AML is associated with the G-1377A polymorphism in the promoter region of the CD95 gene, which affects a SP1 tran- When SNPs detected in the promoter region of the gene probe are assessed in databases and supported by literature surveys, it is very clear that this is the guideline for disease progression and further studies. Our work carries scientific importance in three ways: First, the screened polymorphism in this article seems to be the first results of studied genes in children with leukemia patients. Second, we found that G-1377A polymorphism may be associated with development of leukemia as genetic risk factor. Three, the present study are helpful to provide knowledge to other researchers about included gene variations analyzed in this pathway in childhood leukemia patients.
Conclusion
In conclusion, the results of the current study showed that CD95 gene polymorphisms might have an implication in pediatric leukemias, however, large scale studies are needed. In addition, studies aiming to define the functionality of CD95 gene polymorphism will help clarify the importance of variants at this site.
